Adamis: Up after starting process for clinical trial of COVID-19 treatment

DMK Pharmaceuticals

11/06/2021 12:57

** Drug developer's shares  ADMP.O  rise 9.8% to $1.12
premarket
    ** Co says it has begun process to start clinical trial of
Tempol, its experimental drug for the treatment of early
COVID-19  urn:newsml:reuters.com:*:nGNX93P6m7
    ** Says process started following recently published work by
National Institutes of Health that identified Tempol as a
potential antiviral for COVID-19
    ** Says it is working on identifying trial site, vendor
management and establishment of an independent board of experts
to review safety and efficacy of trial
    ** Goal of study is to evaluate safety and activity of
Tempol in COVID-19 patients early on in the infection
    ** Co has worldwide license to use Tempol to treat
respiratory diseases including asthma and influenza, among other
conditions
    ** As of last close, ADMP stock up 110% YTD

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com;))